mtDNA Targeted Analysis with Heteroplasmy: Known Familial Variant
mtDNA Targeted Analysis with Heteroplasmy: Known Familial Variant
mtDNA Targeted Analysis is a next generation sequencing (NGS) test used to detect a previously identified mtDNA variant. Using NGS allows for the reporting of heteroplasmy level; however, this test may not detect variants with a heteroplasmy level of less than 10%.
Clinical Information
Mitochondrial disorders represent a clinically heterogeneous group of conditions caused by pathogenic variants in either nuclear or mitochondrial DNA (mtDNA). Some mitochondrial disorders affect a single organ while most involve multiple organ systems. Mitochondrial disorders may present at any age and often present with prominent neurologic and myopathic features. Mitochondrial disorders have variable penetrance and severity of symptoms depending on the level of mutant mitochondria, or heteroplasmy, within a given individual or tissue type.
Technical Information
Analysis for a familial variant can be performed using either Sanger sequencing or Next Generation Sequencing (NGS). Sanger sequencing is only able to detect levels of heteroplasmy above 20% while NGS can detect levels as low as 10%. For this reason, Sanger sequencing may be considered as a first step in evaluating for the presence of a familial variant. NGS testing may be reserved for those who appear to be affected or who would be expected to carry the familial variant, but have had negative Sanger sequencing results. As heteroplasmy levels vary from tissue to tissue, a negative blood test cannot completely rule out the chance that an individual carries the familial variant.
Specimen Requirements
Transport Instructions
Associated Tests
Connect With Our Experts
Call 1-800-473-9411 to speak with our team of laboratory genetic counselors for questions or additional information.
Robin Fletcher, MS, CGC
Falecia Thomas, MS, CGC
Alex Finley, MS, CGC
